News

For Valentine’s Day, the senior behavioral scientist at the RAND Corporation talked about the significance of sleep health and romantic relationships [WATCH TIME: 5 minutes]

On diffusion tremor imaging, CMN-Au8 outperformed placebo on domains of fractional anisotropy, radial diffusivity, and mean diffusivity, across all 9 prespecified brain regions and brain white matter.

In honor of International Epilepsy Day, held February 13, 2023, get caught up on some of the latest news in epilepsy as the NeurologyLive® team shares some of our data updates and expert insights.

Dual-task effects were greater for patients with functional gait disorders than controls in gait speed and stride length, but not in stride time variability.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

The director of Cleveland Clinic’s Cerebrovascular Center provided perspective on a new study presented at the International Stroke Conference on experiences of poststroke patients taken directly to angiography suite. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The head of preclinical development at Imbrium Therapeutics provided an overview of positive safe and efficacy findings from the phase 2 study investigating sunobinop. [WATCH TIME: 4 minutes]

The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided perspective on the emergence in antiamyloid therapies, assessing clinically meaningful benefit, and potential changes to trial design in the future. [WATCH TIME: 3 minutes]

Caregivers of patients with advancing PD were more likely to spend more hours caring per day and had a higher self-perceived burden, compared with caregivers for patients with early PD.

Investigators Macarena Hernandez, PhD, and Marc Ribo, MD, provided commentary on positive phase 2a findings assessing ApTOLL in combination with EVT in patients with ischemic stroke.

Neurology News Network for the week ending February 11, 2023. [WATCH TIME: 3 minutes]

Blood pressure medications may not be safe or effective to use for lowering systolic blood pressure following endovascular treatment for acute ischemic stroke.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 10, 2023.

The professor of neurology at Harvard Medical School spoke at the 2023 ISC Conference about highlights from the STROKE-AF study after a 3-year follow-up. [WATCH TIME: 5 minutes]

In comparison with those who underwent additional imaging, patients with large vessel occlusion who directly went to angiography suite had higher mortality, but with no difference in functional outcome.

The chief training and education officer at the Parkinson’s Foundation discussed the inclusion of various medical professionals that assist in Parkinson disease care, and the need to provide access to educational tools to inform clinicians. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Carolina Ferreira Atuesta, MD, MSc. [LISTEN TIME: 26 minutes]

At the conclusion of the trial, treatment with 0.2 mg/kg of ApTOLL with EVT resulted in reduced brain edema and hemorrhagic transformation, as well as fewer deaths than placebo and 0.05 mg groups.

The lead of the Myasthenia Gravis Foundation of America’s Global Myasthenia Gravis Patient Registry spoke about the registry from a research project perspective. [WATCH TIME: 4 minutes]

Patients with noncardioembolic ischemic stroke do not typically monitor post-stroke longterm to detect atrial fibrillation although findings from a trial follow-up suggest otherwise.

Nearly two-third of all participants with REM-sleep behavior disorder had mild cognitive impairment level 2 with multi-domain MCI, but particularly attention and memory deficits.

Catch up on any of the neurology news headlines you may have missed over the course of January 2023, compiled all into one place by the NeurologyLive® team.

REACT randomly assigned 409 patients—treated with either microsurgical clipping or endovascular coiling aneurysm securing procedures—1:1 to placebo or clazosentan 15 mg/hr, for a 14-day treatment period.

The biosimilar form of natalizumab demonstrated similarities to the FDA-approved form in the primary efficacy end point of cumulative number of new active lesions over 24 weeks.

The medical director of stroke at Fairview Hospital, an affiliate of Cleveland Clinic, provided perspective on a new intervention that improves communication and reduces hospital readmission for stroke.

During a 12-week treatment period, investigators observed greater reduction in change from baseline in UPDRS score for those on electroacupuncture than just on PD medication alone.

The assistant professor of neurology at Yale School of Medicine spoke about the importance of the relaunch of the patient registry for research in myasthenia gravis. [WATCH TIME: 3 minutes]